Kyowa Kirin Co., Ltd.

Consolidated Financial Summary (IFRS)
Fiscal 2025 Third Quarter

(January 1, 2025 – September 30, 2025)

This document is an English translation of the Japanese-language original.

SUMMARY OF CONSOLIDATED FINANCIAL STATEMENTS (IFRS)
for Nine Months Ended September 30, 2025

October 30, 2025

Company Name: Kyowa Kirin Co., Ltd.
Listed Exchanges: Tokyo Stock Exchange
Stock Code: 4151
President & Chief Operating Officer: Abdul Mullick
Telephone: +81 3 5205 7206
Inquiries: Hiroki Nakamura
Executive Vice President,
Corporate Communications Department
URL: https://www.kyowakirin.com/index.html
Scheduled start date of dividend payment: –
Appendix materials to accompany the financial report: Yes
Results presentation meeting: Yes (for institutional investors and securities analysts)

(Millions of yen rounded off)

1. Consolidated Financial Results for the Nine Months Ended September 30, 2025

(1) Consolidated operating results

(Percentages indicate year-on-year changes.)

	Revenue		Core operating profit		Profit before tax		Profit	
Nine months ended	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
September 30, 2025	349,451	(3.7)	61,993	(16.7)	47,924	(33.0)	32,599	(41.7)
September 30, 2024	362,798	18.5	74,416	22.2	71,573	11.2	55,901	4.4

Total comprehensive income: Nine months ended September 30, 2025: ¥25,998 million; (60.7)%
Nine months ended September 30, 2024: ¥66,170 million; (15.1)%

Note: Core operating profit was calculated by deducting “selling, general and administrative expenses” and “research and development expenses” from “gross profit,” and adding “share of profit (loss) of investments accounted for using equity method” to the amount.

	Profit attributable to owners of parent		Basic earnings per share	Diluted earnings per share
Nine months ended	Millions of yen	%	Yen	Yen
September 30, 2025	32,599	(41.7)	62.28	62.28
September 30, 2024	55,901	4.4	105.20	105.19

(2) Consolidated financial position

	Total assets	Total equity	Equity attributable to owners of parent	Ratio of equity attributable to owners of parent to total assets
As of	Millions of yen	Millions of yen	Millions of yen	%
September 30, 2025	1,077,447	846,123	846,123	78.5
December 31, 2024	1,067,363	850,811	850,811	79.7

2. Dividends

	Dividends per share				
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended December 31, 2024	–	29.00	–	29.00	58.00
Fiscal year ending December 31, 2025	–	30.00	–		
Fiscal year ending December 31, 2025 (Forecast)				30.00	60.00

Note: Revisions to the dividend forecast most recently announced: None

3. Consolidated Earnings Forecasts for the Fiscal Year Ending December 31, 2025 (from January 1, 2025 to December 31, 2025)

(Percentages indicate year-on-year changes.)

	Revenue		Core operating profit		Profit before tax		Profit		Profit attributable to owners of parent		Basic earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Full year	478,000	(3.5)	80,000	(16.1)	74,000	(11.3)	57,000	(4.8)	57,000	(4.8)	108.91

Note: Changes to the earnings forecasts most recently announced: None

* Notes

(1) Significant changes in the scope of consolidation during the period under review: No

(2) Changes in accounting policies, and accounting estimates:

a. Changes in accounting policies required by IFRS: No

b. Changes in accounting policies other than a. above: No

c. Changes in accounting estimates: No

(3) Number of shares issued (ordinary shares)

a. Number of shares issued (including treasury shares)

As of September 30, 2025	525,634,500 shares
As of December 31, 2024	525,634,500 shares

b. Number of treasury shares

As of September 30, 2025	2,145,031 shares
As of December 31, 2024	2,276,724 shares

c. Average number of shares during the period

Nine months ended September 30, 2025	523,440,518 shares
Nine months ended September 30, 2024	531,380,426 shares

* Review of the Japanese-language originals of the attached quarterly consolidated financial statements by certified public accountants or an audit corporation: None

* Notice regarding the appropriate use of the earnings forecasts and other special comments
The forward-looking statements, including earnings forecasts, contained in these materials are based on the information currently available to the Company and on certain assumptions deemed to be reasonable by management. As such, they do not constitute guarantees by the Company of future performance. Actual results may differ materially from these projections for a wide variety of reasons.

Attachment Index

1. Summary of Business Performance and Financial Position 4
(1) Summary of Quarterly Consolidated Financial Position 4
(2) Summary of Quarterly Consolidated Business Performance 5
(3) Summary of Quarterly Consolidated Cash Flows 9
(4) Research and Development Activities 10
(5) Summary of Consolidated Earnings Forecasts and Other Forward-looking Statements 14
2. Condensed Quarterly Consolidated Financial Statements and Significant Notes Thereto 15
(1) Condensed Quarterly Consolidated Statement of Financial Position 15
(2) Condensed Quarterly Consolidated Statement of Profit or Loss and Condensed Quarterly Consolidated Statement of Comprehensive Income 17
(3) Condensed Quarterly Consolidated Statement of Changes in Equity 19
(4) Condensed Quarterly Consolidated Statement of Cash Flows 21
(5) Notes to Condensed Quarterly Consolidated Financial Statements 23
Notes on going concern assumption *23*
Segment information *23*
Changes in presentation *23*
Cash flow information *23*

1. Summary of Business Performance and Financial Position

(1) Summary of Quarterly Consolidated Financial Position

(Billions of yen)

	As of December 31, 2024	As of September 30, 2025	Year-on-year change
Assets	1,067.4	1,077.4	10.1
Non-current assets	563.3	586.7	23.3
Current assets	504.0	490.8	(13.2)
Liabilities	216.6	231.3	14.8
Equity	850.8	846.1	(4.7)
Ratio of equity attributable to owners of parent to total assets (%)	79.7%	78.5%	(1.2)%

- Assets as of September 30, 2025, were ¥1,077.4 billion, an increase of ¥10.1 billion compared to the end of the previous fiscal year.
  - Non-current assets increased by ¥23.3 billion compared to the end of the previous fiscal year, to ¥586.7 billion, due mainly to increases in property, plant and equipment and intangible assets, despite a decrease in deferred tax assets.
  - Current assets decreased by ¥13.2 billion compared to the end of the previous fiscal year, to ¥490.8 billion, due mainly to a decrease in trade and other receivables.
- Liabilities as of September 30, 2025, were ¥231.3 billion, an increase of ¥14.8 billion compared to the end of the previous fiscal year, due mainly to increases in income taxes payable and other financial liabilities.
- Equity as of September 30, 2025, was ¥846.1 billion, a decrease of ¥4.7 billion compared to the end of the previous fiscal year, due mainly to a decrease due to the payment of dividends, in addition to a decrease in exchange differences on translation of foreign operations resulting from the impact of exchange rates, despite the recording of profit attributable to owners of parent. As a result, the ratio of equity attributable to owners of parent to total assets as of September 30, 2025 was 78.5%, a decrease of 1.2 percentage points compared to the end of the previous fiscal year.



(2) Summary of Quarterly Consolidated Business Performance

1) Overview of results

The Group now applies the International Financial Reporting Standards (“IFRS”) in line with its policy of expanding business globally, and adopts “core operating profit” as a level of profit that shows the recurring profitability from operating activities. Core operating profit is calculated by deducting “selling, general and administrative expenses” and “research and development expenses” from “gross profit,” and adding “share of profit (loss) of investments accounted for using equity method” to the amount.

(Billions of yen)

	Nine months ended September 30, 2024	Nine months ended September 30, 2025	Year-on-year change	Rate of change (%)
Revenue	362.8	349.5	(13.3)	(3.7)%
Core operating profit	74.4	62.0	(12.4)	(16.7)%
Profit before tax	71.6	47.9	(23.6)	(33.0)%
Profit attributable to owners of parent	55.9	32.6	(23.3)	(41.7)%

<Average exchange rates for each period>

Currency	Nine months ended September 30, 2024	Nine months ended September 30, 2025	Year-on-year change
USD (USD/¥)	¥151	¥149	Down ¥2
GBP (GBP/¥)	¥193	¥195	Up ¥2
EUR (EUR/¥)	¥164	¥165	Up ¥1

For the nine months ended September 30, 2025 (January 1, 2025 to September 30, 2025), revenue was ¥349.5 billion (down 3.7% compared to the same period of the previous fiscal year), and core operating profit was ¥62.0 billion (down 16.7%). Profit attributable to owners of parent was ¥32.6 billion (down 41.7%).

- Revenue decreased due mainly to the impact of the business restructuring in the APAC region and the impact of the reductions in drug price standards, despite the growth of global strategic products mainly in North America and EMEA. The negative effect on revenue from foreign exchange was ¥3.9 billion.
- Core operating profit decreased due mainly to an increase in research and development expenses, in addition to a decrease in gross profit. The negative effect on core operating profit from foreign exchange was ¥2.3 billion.
- Profit attributable to owners of parent decreased due mainly to a decrease in core operating profit and the recording of gain on sale of investments in subsidiaries in China in the same period of the previous fiscal year, leading to a decrease in other income.

2) Revenue by regional control function

(Billions of yen)

	Nine months ended September 30, 2024	Nine months ended September 30, 2025	Year-on-year change	Rate of change (%)
Japan	98.0	89.7	(8.3)	(8.5)%
North America	120.1	129.9	9.8	8.2%
EMEA	65.7	62.4	(3.3)	(5.1)%
Others	78.9	67.5	(11.5)	(14.5)%
Total consolidated revenue	362.8	349.5	(13.3)	(3.7)%

Notes:
1. Revenue by regional control function is classified based on consolidated revenue from products of regional control functions in the One Kyowa Kirin (OKK) matrix global management structure, which combines a regional organization, a functional organization, and a product organization (product franchises).
2. EMEA consists of Europe, the Middle East, Africa, etc.
3. Others consists of revenue from technology out-licensing, hematopoietic stem cell gene therapy (revenue from Orchard Therapeutics), original equipment manufacturing, etc.
4. In conjunction with the business restructuring of the APAC region in 2024, the APAC revenue (¥35.0 billion) that was presented separately for the nine months ended September 30, 2024, has been included in "Other" since the first quarter of the fiscal year ended December 31, 2025.

Composition of revenue by regional control function









<Revenue in Japan region>

(Billions of yen)

	Nine months ended September 30, 2024	Nine months ended September 30, 2025	Year-on-year change	Rate of change (%)
Crysvita	8.2	9.7	1.5	18.3%
Darbepoetin Alfa Injection Syringe [KKF]	8.5	7.6	(0.8)	(9.9)%
Duvroq	8.9	10.9	2.0	22.2%
PHOZEVEL	2.9	5.9	3.0	103.8%
G-Lasta	15.3	13.7	(1.6)	(10.5)%
Dovobet	5.8	–	(5.8)	–

- Revenue in Japan decreased year on year due mainly to the impact of the termination of the distribution and co-promotion agreement for the psoriasis vulgaris treatment Dovobet and the reductions in drug price standards implemented in April 2024 and April 2025, despite the growth in sales of PHOZEVEL, a treatment for hyperphosphatemia, etc.
  - Revenue from Crysvita, a treatment for FGF23-related diseases, has been growing steadily since its launch in 2019.
  - Revenue from Darbepoetin Alfa Injection Syringe [KKF], a treatment for renal anemia, decreased due to the impact of the reductions in drug price standards and the market penetration of rival products.
  - Revenue from Duvroq, a treatment for renal anemia, has been growing steadily since its launch in 2020.
  - Revenue from PHOZEVEL, a treatment for hyperphosphatemia, has been growing steadily since its launch in February 2024.
  - Revenue from G-Lasta, an agent for decreasing the incidence of febrile neutropenia, decreased due to the impact of biosimilar products and the impact of the reductions in drug price standards.
  - Revenue from Dovobet, a psoriasis vulgaris treatment, decreased due to the termination of the distribution and co-promotion agreement with LEO Pharma K.K. on December 31, 2024.

<Revenue from overseas regions and Others>

(Billions of yen)

	Nine months ended September 30, 2024	Nine months ended September 30, 2025	Year-on-year change	Rate of change (%)
Crysvita	126.7	137.0	10.4	8.2%
Poteligeo	27.7	32.5	4.8	17.3%
Libmeldy/Lenmeldy	2.2	4.4	2.2	103.3%

- Revenue in North America increased year on year due to the growth of global strategic products.
  - Revenue from Crysvita, a treatment for X-linked hypophosphatemia, has been growing steadily since its launch in 2018.
  - Revenue from Poteligeo, an anticancer agent, has been growing since its launch in 2018.

- Revenue in EMEA decreased year on year due to the recording of proceeds from transfer of rights to three brands of ¥13.1 billion (£66.4 million) in 2024, despite factors such as growth of global strategic products and proceeds from transfer of rights to one brand.
  - Revenue from Crysvita, a treatment for X-linked hypophosphatemia, has been growing since its launch in 2018, as the number of countries where it has been released and its indications have expanded.
  - Revenue from Poteligeo, an anticancer agent, has been growing as the number of countries where it has been released has been increasing since its launch in 2020.

- Revenue of ¥6.1 billion (£30.6 million) was recorded in July 2025 due to the transfer of the rights (intellectual property) for one brand of established medicines to the joint venture. The amount includes the price adjustment differences related to the three brands transferred in July 2024.

- Revenue from Others decreased year on year due to the impact of the business restructuring in the APAC region.
  - Revenue from Libmeldy/Lenmeldy, a treatment for metachromatic leukodystrophy (MLD), grew steadily due to sales beginning to be recorded in the U.S., in addition to solid sales in Europe.
  - Revenue from technology out-licensing increased due to an increase in royalties revenue from AstraZeneca in relation to benralizumab.
  - In conjunction with the business restructuring in the APAC region at the end of September 2024, revenue from established medicines, etc. significantly decreased (¥16.1 billion).

3) Core operating profit



- Core operating profit decreased year on year due mainly to a decrease in gross profit, in addition to an increase in research and development expenses and a decrease in share of profit (loss) of investments accounted for using equity method.

(3) Summary of Quarterly Consolidated Cash Flows

(Billions of yen)

	Nine months ended September 30, 2024	Nine months ended September 30, 2025	Year-on-year change	Rate of change (%)
Net cash provided by (used in) operating activities	69.6	69.6	0.0	0.0%
Net cash provided by (used in) investing activities	(95.8)	(41.6)	54.2	(56.5)%
Net cash provided by (used in) financing activities	(83.7)	(33.6)	50.1	(59.8)%
Cash and cash equivalents at beginning of period	403.1	244.7	(158.4)	(39.3)%
Cash and cash equivalents at end of period	296.3	240.2	(56.1)	(18.9)%

- Cash and cash equivalents as of September 30, 2025 were ¥240.2 billion, a decrease of ¥4.5 billion compared with the balance of ¥244.7 billion as of December 31, 2024.
  The main contributing factors affecting cash flow during the nine months ended September 30, 2025 were as follows:
- Net cash provided by operating activities was ¥69.6 billion, compared with net cash provided by operating activities of ¥69.6 billion in the same period of the previous fiscal year. The major inflows were profit before tax of ¥47.9 billion and depreciation and amortization of ¥18.8 billion. A major outflow was a decrease in contract liabilities of ¥5.8 billion.
- Net cash used in investing activities was ¥41.6 billion, compared with net cash used in investing activities of ¥95.8 billion in the same period of the previous fiscal year. Major outflows were purchase of property, plant and equipment of ¥24.3 billion, purchase of intangible assets of ¥13.0 billion, and transfers to escrow account of ¥7.7 billion, which is a part of the construction funds for a new biopharmaceutical drug substance manufacturing building.
- Net cash used in financing activities was ¥33.6 billion, compared with net cash used in financing activities of ¥83.7 billion in the same period of the previous fiscal year. A major outflow was dividends paid of ¥30.9 billion.



(4) Research and Development Activities

The Group continuously and actively invests management resources in research and development activities. The Group aims to continually create new drugs with life-changing value by including bone and mineral, intractable hematological diseases and hemato oncology, and rare disease in the disease science field in which is the area of focus for its in-house research and development, and, with regard to drug discovery technology, strengthening innovative modalities such as advanced antibody technologies and hematopoietic stem cell gene therapy. As part of the value creating process, the Group will also promote open innovation activities, collaborate with partners, invest in venture capital funds, and utilize corporate venture capital. In research and development, the Group will focus on creating life-changing value and utilize a business model that not only aims to maximize value through our own global deployment, but also through strategic collaboration with external partners.

For the nine months ended September 30, 2025, the Group's research and development expenses totaled ¥76.8 billion.

<Development status of major development products>

As of September 30, 2025

Code, Generic Name	Indication	Development status
KHK4083/AMG 451, rocatinlimab	Moderate and severe atopic dermatitis	Ph III clinical study: in progress
	Prurigo nodularis	Ph III clinical study: in progress
	Moderate and severe asthma	Ph II clinical study: in progress
ziftomenib	Adult Relapsed or Refractory (R/R) NPM1-mutant Acute Myeloid Leukemia (AML) (monotherapy)	Regulatory submission Ph II clinical study: detailed results reported
	Acute Lymphoblastic Leukemia (ALL) (monotherapy)	Ph I clinical study: in progress
	Acute Myeloid Leukemia (AML) (combination)	Ph I clinical study: in progress
		Ph III clinical study: in progress
OTL-203	Mucopolysaccharidosis type IH (Hurler syndrome)	Pivotal study (Equivalent to Ph III study): in progress
KK8398, infigratinib	Achondroplasia	Ph III clinical study: preparation underway
KHK4951, tivozanib	Neovascular Age-related Macular Degeneration (nAMD)	Ph II clinical study: in progress
	Diabetic Macular Edema (DME)	Ph II clinical study: in progress
OTL-201	Mucopolysaccharidosis type IIIA (Sanfilippo syndrome type A)	PoC study (Equivalent to Ph I/II study): in progress
KK4277	Systemic Erythematosus (SLE)/Cutaneous Lupus Erythematosus (CLE)	Ph I clinical study: in progress
KK2260	Advanced or metastatic solid tumors	Ph I clinical study: in progress
KK2269	Advanced or metastatic solid tumors	Ph I clinical study: in progress
KK2845	Acute Myeloid Leukemia (AML)	Ph I clinical study: in progress
KK8123	X-linked Hypophosphatemia (XLH)	Ph I clinical study: in progress
KK3910	Essential Hypertension	Ph I clinical study: in progress

- KHK4083/AMG 451 (rocatinlimab) is a potential T cell rebalancing monoclonal antibody that is designed to selectively inhibit and reduce pathogenic T cells by targeting the OX40 receptor. One of the major causes of chronic inflammatory diseases including atopic dermatitis is due to the activation of T cells through OX40 signaling, leading to an increase in pathogenic T cells and induction of their effector functions. By selectively targeting the OX40 receptor, rocatinlimab may promote T cell

rebalancing by suppressing the activity and number of pathogenic T cells. Its novel mechanism of action may lead to reduced disease chronicity and relapse, particularly by directly acting on memory T cells, and thus may offer symptom control with reduced dosing frequency, distinguishing it from conventional cytokine blockers and JAK inhibitors. The initial antibody was discovered in collaboration between research team of Kyowa Kirin in United States and La Jolla Institute for Immunology. On June 1, 2021, Kyowa Kirin and Amgen entered into an agreement to jointly develop and commercialize rocatinlimab. Under the terms of the agreement, Amgen will lead the development, manufacturing, and commercialization for rocatinlimab for all markets globally, except Japan, where Kyowa Kirin will retain all rights. If approved, the companies will co-promote the asset in the United States and Kyowa Kirin has opt-in rights to co-promote in certain other markets including Europe and Asia. Phase III clinical studies evaluating rocatinlimab in moderate to severe atopic dermatitis (ROCKET Program) is composed of eight studies enrolling adult and adolescent patients. To date, over 3,300 patients have been enrolled in the ROCKET Program with seven studies having completed enrollment. HORIZON, IGNITE, SHUTTLE, and VOYAGER, which are part of the phase III trials in the ROCKET Program, met their coprimary endpoints and all key secondary endpoints as of June 2025. Amgen and Kyowa Kirin also announced top-line results from the interim analysis of the ASCEND study, one of the eight studies. In addition to the ROCKET Program, a Phase II clinical study in moderate to severe asthma and a Phase III clinical study in prurigo nodularis are being conducted.

- Ziftomenib is an oral menin inhibitor in development by Kura Oncology, Inc. for the treatment of genetically defined AML patients with high unmet need. In November 2024, Kura Oncology and Kyowa Kirin entered into a global strategic collaboration to develop and commercialize ziftomenib in acute leukemias. Under the terms of the agreement, the companies will jointly develop and commercialize ziftomenib. Kura Oncology, Inc. will lead development, regulatory and commercial strategy in the U.S. Outside the U.S., Kyowa Kirin will lead development, regulatory and commercial strategy. Multiple clinical trials are currently in progress for AML. Kura Oncology, Inc. submitted a New Drug Application (NDA) for ziftomenib for the treatment of adult patients with R/R NPM1-mutant AML to the U.S. Food and Drug Administration (FDA) in March 2025, and it was accepted in May. FDA accepted the NDA and the application has been granted Priority Review and assigned a Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2025. Kura Oncology, Inc. and Kyowa Kirin reported positive pivotal monotherapy data from the KOMET-001 Phase 2 registration-directed trial of ziftomenib for R/R NPM1-mutant AML at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in June 2025. Pivotal clinical data on ziftomenib in R/R NPM1-mutant AML was published in the Journal of Clinical Oncology in September. They also presented positive updated combination therapy data from KOMET-007, a Phase 1a/1b trial of ziftomenib in patients with frontline NPM1-mutant and KMT2A-rearranged AML at the European Hematology Association 2025 Congress (EHA2025) in June 2025. Furthermore, Kura Oncology, Inc. and Kyowa Kirin started Phase 3 KOMET-017 trial for newly diagnosed NPM1-mutant or KMT2A-rearranged AML patients in September 2025.

- OTL-203 is an investigational HSC gene therapy in development for the treatment of mucopolysaccharidosis type IH (Hurler syndrome). Orchard Therapeutics is currently implementing a registrational study (equivalent to a Phase III clinical study) of OTL-203 as a therapy to potentially correct the underlying cause of Hurler syndrome.

- KK8398 (infigratinib) is a small-molecular FGFR3 inhibitor, which has been developed for bone diseases by QED Therapeutics, wholly owned by BridgeBio. In February 2024, a partnership wherein QED Therapeutics, grants Kyowa Kirin an exclusive license to develop and commercialize infigratinib for achondroplasia, hypochondroplasia, and other skeletal dysplasias in Japan. The Company is currently preparing for Phase III clinical trial for achondroplasia in Japan.

- Tivozanib, the active ingredient of KHK4951 is a small-molecule vascular endothelial growth factor receptor (VEGFR) -1, -2, and -3 tyrosine kinase inhibitor (TKI) discovered and developed by Kyowa Kirin. KHK4951 is a novel nano-crystalized tivozanib eye drops designed to deliver it efficiently to the posterior ocular tissues and has the potential to provide a novel non-invasive treatment option for patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Phase II clinical studies are ongoing.

- OTL-201 is an investigational HSC gene therapy in development for the treatment of mucopolysaccharidosis type IIIA (Sanfilippo syndrome). A proof-of-concept (Equivalent to Phase I / II study) is ongoing.

- KK4277 is an optimized antibody based on antibodies licensed from SBI Biotech. It has been enhanced with antibody-dependent cell-mediated cytotoxicity (ADCC) activity using our POTELLIGENT technology. Phase I clinical study for the treatment of systemic lupus erythematosus and cutaneous lupus erythematosus has been conducted.

- KK2260 is an EGFR-TfR1 bispecific antibody developed using the Company’s proprietary bispecific antibody technology REGULGENT. It is designed as an antibody that achieves selective iron depletion in cancer cells, and in non-clinical trials it showed high efficacy and tolerability. Phase I clinical trial is ongoing.

- KK2269 is an EpCAM-CD40 bispecific antibody developed using the Company’s proprietary bispecific antibody technology REGULGENT. It is designed as an antibody that activates only antigen-presenting cells near the tumor by cross-linking EpCAM, which is highly expressed in various tumors, with CD40 on antigen-presenting cells. In non-clinical trials, it was found to exhibit the therapeutic effects of anti-tumor immunity while suppressing systemic side effects. Phase I clinical trial is ongoing.

- KK2845 is the Company’s first antibody-drug conjugate (ADC). The target molecule is TIM-3, Phase I clinical trial for acute myeloid leukemia (AML) is ongoing.

- KK8123 is a human antibody targeting FGF23. Phase I study for XLH is ongoing.

- KK3910 is an antibody developed by Kyowa Kirin. Phase I clinical trial for healthy adults and essential hypertension is ongoing.

R&D pipeline

small molecule　antibody　HSC-GT　Updated since Dec. 31, 2024　✓ Updated since Jun. 30, 2025

As of Sep 30, 2025

Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage			[In-House or Licensed] Remarks
			PhI	PhII	PhIII	
KK8123 Injection	Anti-FGF23 Fully Human Antibody	X-linked Hypophosphatemia				[In-House] Clinical study is being conducted in NA and EU as a global product
KK8398 infigratinib Oral	FGFR3 Inhibitor	Achondroplasia				[QED Therapeutics] Preparation underway for Ph Ⅲ in JP
ziftomenib ※ Oral	Menin Inhibitor	Acute Myeloid Leukemia (AML) （Monotherapy）				[Kura Oncology] The detailed results presented at ASCO in June 2025 and published on JCO in September 2025 Adult Relapsed or Refractory AML with a NPM1 Mutation KOMET-001
		Acute Lymphoblastic Leukemia（ALL） （Monotherapy）				Clinical study is being conducted in NA and EU as a global product KMT2A-rearranged ALL KOMET-001
		Acute Myeloid Leukemia (AML) （Monotherapy）				Clinical study is being conducted in NA and EU as a global product Non-NPM1-mutant AML/Non-KMT2A-rearranged AML KOMET-001
		Acute Myeloid Leukemia (AML) （Combination）				Clinical study is being conducted in NA as a global product NPM1-mutant AML/KMT2A-rearranged AML Combinations with venetoclax + azacitidine, and cytarabine + daunorubicin KOMET-007
						Clinical study is being conducted in NA and EU as a global product NPM1-mutant AML/KMT2A-rearranged AML Combinations with gilteritinib, FLAG-IDA, LDAC KOMET-008
					✓	Clinical study is being conducted as a global product NPM1-mutant AML/KMT2A-rearranged AML Combinations with venetoclax + azacitidine, and cytarabine + daunorubicin KOMET-017
KK2845	Anti-TIM-3 ADC	Acute Myeloid Leukemia（AML）				[In-House] Antibody-Drug Conjugate Clinical study is being conducted in JP as a global product
OTL-203	Hematopoietic Stem Cell (HSC) Gene Therapy	MPS-IH (Hurler Syndrome)				[In-House] Rare Pediatric Disease (RPD) and Fast Track designations (FDA) Priority Medicines (PRIME) designation (EMA) Area of clinical study: NA and EU
OTL-201	Hematopoietic Stem Cell (HSC) Gene Therapy	MPS-IIIA (Sanfilippo Syndrome type A)		Ph Ⅰ/Ⅱ		[In-House] Rare Pediatric Disease (RPD) designation (FDA) Preparation underway for registrational study (equivalent to PhⅢ study)
KHK4083/AMG 451 rocatinlimab Injection	Anti-OX40 Antibody	Moderate to Severe Atopic Dermatitis				[In-House] POTELLIGENT Human monoclonal antibody production technology Collaboration agreement with Amgen for the development of rocatinlimab in all the countries except for Japan Clinical study is being conducted in JP, NA, EU, UK, Middle East, Asia, Oceania, and other regions as a global product
		Prurigo Nodularis				Clinical study is being conducted in JP, NA, EU, Asia, and Oceania as a global product
		Moderate to Severe Asthma				Clinical study is being conducted in JP, NA, EU, Asia, and Oceania as a global product
KHK4951 tivozanib Ophthalmic	VEGF Receptor Tyrosine Kinase Inhibitor	Diabetic Macular Edema				[In-House] Clinical study is being conducted in JP, NA, Asia, and Oceania as a global product
		Neovascular Age-Related Macular Degeneration				Clinical study is being conducted in JP, NA, Asia, and Oceania as a global product
KK2260 Injection	EGFR-TfR1Bispecific Antibody	Advanced or Metastatic Solid Tumors				[In-House] REGULGENT Fully human antibody production technology Clinical study is being conducted in JP, and a clinical study is prepared under way for PhI in NA as a global product

As of Sep 30, 2025

Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage			[In-House or Licensed] Remarks
			PhI	PhII	PhIII	
KK2269 Injection	EpCAM-CD40Bispecific Antibody	Advanced or Metastatic Solid Tumors				[In-House] REGULGENT Fully human antibody production technology Clinical study is being conducted in JP and NA as a global product
KK4277 Injection	Anti-PTPRS Humanized Antibody	Systemic Lupus Erythematosus/Cutaneous Lupus Erythematosus				[SBI Biotech] POTELLIGENT Clinical study is being conducted in JP and Asia
KK3910 Injection		Essential Hypertension				[In-House] Clinical study is being conducted in JP as a global product

※ For detailed information on ziftomenib's development status, please refer to Kura Oncology's website. https://kuraoncology.com/

Note: Our main progress from September 30, 2025 is as follows.

- Launch of clinical trial of ziftomenib evaluating dual inhibition of NPM1 and FLT3 mutations in patients with newly diagnosed AML (KOMET-007) was announced on October 2, 2025.
- OTL-200 was granted orphan regenerative medicine product designation for early-onset MLD in Japan in October 2025.

Major Applications and Approvals

Code Name, Generic Name, Product Name	Indication	Application/ Under Review	Countries/ Regions Received Approval in 2025
ziftomenib	Adult Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) with a Nucelophosmin1 (NPM1) Mutation	US	—

(5) Summary of Consolidated Earnings Forecasts and Other Forward-looking Statements

No revisions have been made to the consolidated earnings forecasts announced on February 6, 2025.

2. Condensed Quarterly Consolidated Financial Statements and Significant Notes Thereto

(1) Condensed Quarterly Consolidated Statement of Financial Position

(Millions of yen)

	As of December 31, 2024	As of September 30, 2025
Assets		
Non-current assets		
Property, plant and equipment	111,477	130,799
Goodwill	181,034	179,111
Intangible assets	165,297	175,018
Investments accounted for using equity method	3,185	0
Other financial assets	32,800	34,966
Retirement benefit asset	19,775	21,845
Deferred tax assets	41,258	35,640
Other non-current assets	8,511	9,271
Total non-current assets	563,337	586,651
Current assets		
Inventories	72,933	71,277
Trade and other receivables	157,015	151,827
Other financial assets	1,705	1,970
Other current assets	27,692	25,512
Cash and cash equivalents	244,681	240,211
Total current assets	504,026	490,797
Total assets	1,067,363	1,077,447

(1) Condensed Quarterly Consolidated Statement of Financial Position (continued)

(Millions of yen)

	As of December 31, 2024	As of September 30, 2025
Equity		
Share capital	26,745	26,745
Capital surplus	427,733	427,723
Treasury shares	(5,887)	(5,654)
Retained earnings	371,050	372,801
Other components of equity	31,171	24,507
Total equity attributable to owners of parent	850,811	846,123
Total equity	850,811	846,123
Liabilities		
Non-current liabilities		
Liabilities from application of equity method	11,695	11,376
Retirement benefit liability	272	289
Provisions	6,470	7,224
Deferred tax liabilities	434	400
Other financial liabilities	24,119	22,974
Other non-current liabilities	8,887	3,901
Total non-current liabilities	51,876	46,165
Current liabilities		
Trade and other payables	121,063	123,720
Provisions	4,441	5,286
Other financial liabilities	4,628	10,909
Income taxes payable	3,384	11,521
Other current liabilities	31,159	33,723
Total current liabilities	164,675	185,160
Total liabilities	216,551	231,324
Total equity and liabilities	1,067,363	1,077,447

(2) Condensed Quarterly Consolidated Statement of Profit or Loss and Condensed Quarterly Consolidated Statement of Comprehensive Income

Condensed Quarterly Consolidated Statement of Profit or Loss

(Millions of yen)

	January 1, 2024 to September 30, 2024	January 1, 2025 to September 30, 2025
Revenue	362,798	349,451
Cost of sales	(94,006)	(90,061)
Gross profit	268,792	259,390
Selling, general and administrative expenses	(123,617)	(121,548)
Research and development expenses	(74,293)	(76,835)
Share of profit (loss) of investments accounted for using equity method	3,534	985
Other income	13,264	749
Other expenses	(16,880)	(14,740)
Finance income	2,669	3,132
Finance costs	(1,896)	(3,209)
Profit before tax	71,573	47,924
Income tax expense	(15,672)	(15,326)
Profit	55,901	32,599
Profit attributable to		
Owners of parent	55,901	32,599
Earnings per share		
Basic earnings per share (Yen)	105.20	62.28
Diluted earnings per share (Yen)	105.19	62.28

Condensed Quarterly Consolidated Statement of Comprehensive Income

(Millions of yen)

	January 1, 2024 to September 30, 2024	January 1, 2025 to September 30, 2025
Profit	55,901	32,599
Other comprehensive income		
Items that will not be reclassified to profit or loss		
Financial assets measured at fair value through other comprehensive income	334	(139)
Remeasurements of defined benefit plans	127	–
Total of items that will not be reclassified to profit or loss	461	(139)
Items that may be reclassified to profit or loss		
Exchange differences on translation of foreign operations	7,913	(6,196)
Cash flow hedges	1,798	–
Share of other comprehensive income of investments accounted for using equity method	96	(266)
Total of items that may be reclassified to profit or loss	9,808	(6,462)
Other comprehensive income	10,269	(6,601)
Comprehensive income	66,170	25,998
Comprehensive income attributable to		
Owners of parent	66,170	25,998

(3) Condensed Quarterly Consolidated Statement of Changes in Equity

January 1, 2024 to September 30, 2024

(Millions of yen)

	Equity attributable to owners of parent					
					Other components of equity	
	Share capital	Capital surplus	Treasury shares	Retained earnings	Share acquisition rights	Exchange differences on translation of foreign operations
Balance at January 1, 2024	26,745	464,731	(2,933)	338,764	102	8,823
Profit	–	–	–	55,901	–	–
Other comprehensive income	–	–	–	–	–	8,010
Total comprehensive income	–	–	–	55,901	–	8,010
Dividends of surplus	–	–	–	(30,895)	–	–
Purchase of treasury shares	–	–	(36,418)	–	–	–
Disposal of treasury shares	–	(135)	68	–	–	–
Share-based remuneration transactions	–	68	11	–	(40)	–
Transfer from other components of equity to retained earnings	–	–	–	127	–	–
Total transactions with owners	–	(67)	(36,339)	(30,767)	(40)	–
Balance at September 30, 2024	26,745	464,664	(39,272)	363,898	63	16,833

	Equity attributable to owners of parent					Total equity
	Other components of equity				Total	
	Financial assets measured at fair value through other comprehensive income	Remeasure-ments of defined benefit plans	Cash flow hedges	Total		
Balance at January 1, 2024	1,984	–	(1,798)	9,112	836,418	836,418
Profit	–	–	–	–	55,901	55,901
Other comprehensive income	334	127	1,798	10,269	10,269	10,269
Total comprehensive income	334	127	1,798	10,269	66,170	66,170
Dividends of surplus	–	–	–	–	(30,895)	(30,895)
Purchase of treasury shares	–	–	–	–	(36,418)	(36,418)
Disposal of treasury shares	–	–	–	–	(67)	(67)
Share-based remuneration transactions	–	–	–	(40)	39	39
Transfer from other components of equity to retained earnings	–	(127)	–	(127)	–	–
Total transactions with owners	–	(127)	–	(167)	(67,340)	(67,340)
Balance at September 30, 2024	2,318	–	–	19,214	835,248	835,248

(3) Condensed Quarterly Consolidated Statement of Changes in Equity (continued)

January 1, 2025 to September 30, 2025

(Millions of yen)

	Equity attributable to owners of parent					
					Other components of equity	
	Share capital	Capital surplus	Treasury shares	Retained earnings	Share acquisition rights	Exchange differences on translation of foreign operations
Balance at January 1, 2025	26,745	427,733	(5,887)	371,050	27	30,661
Profit	–	–	–	32,599	–	–
Other comprehensive income	–	–	–	–	–	(6,462)
Total comprehensive income	–	–	–	32,599	–	(6,462)
Dividends of surplus	–	–	–	(30,882)	–	–
Purchase of treasury shares	–	–	(6)	–	–	–
Disposal of treasury shares	–	(8)	56	–	–	–
Share-based remuneration transactions	–	(3)	183	–	(27)	–
Transfer from other components of equity to retained earnings	–	–	–	35	–	–
Total transactions with owners	–	(10)	233	(30,847)	(27)	–
Balance at September 30, 2025	26,745	427,723	(5,654)	372,801	–	24,199

	Equity attributable to owners of parent					Total equity
	Other components of equity				Total	
	Financial assets measured at fair value through other comprehensive income	Remeasure-ments of defined benefit plans	Cash flow hedges	Total		
Balance at January 1, 2025	482	–	–	31,171	850,811	850,811
Profit	–	–	–	–	32,599	32,599
Other comprehensive income	(139)	–	–	(6,601)	(6,601)	(6,601)
Total comprehensive income	(139)	–	–	(6,601)	25,998	25,998
Dividends of surplus	–	–	–	–	(30,882)	(30,882)
Purchase of treasury shares	–	–	–	–	(6)	(6)
Disposal of treasury shares	–	–	–	–	48	48
Share-based remuneration transactions	–	–	–	(27)	153	153
Transfer from other components of equity to retained earnings	(35)	–	–	(35)	–	–
Total transactions with owners	(35)	–	–	(62)	(30,686)	(30,686)
Balance at September 30, 2025	309	–	–	24,507	846,123	846,123

(4) Condensed Quarterly Consolidated Statement of Cash Flows

(Millions of yen)

	January 1, 2024 to September 30, 2024	January 1, 2025 to September 30, 2025
Cash flows from operating activities		
Profit before tax	71,573	47,924
Depreciation and amortization	18,798	18,752
Impairment losses (reversal of impairment losses)	1,535	1,307
Increase (decrease) in provisions	622	1,530
Share of loss (profit) of investments accounted for using equity method	(3,534)	(985)
Gain on sales of share and valuation of remaining share (gain)	(7,840)	–
Foreign exchange loss (gain)	7,288	600
Decrease (increase) in inventories	(1,784)	70
Decrease (increase) in trade receivables	(15,696)	1,511
Increase (decrease) in trade payables	(3,418)	(1,955)
Increase (decrease) in contract liabilities	(7,892)	(5,845)
Income taxes refund (paid)	(12,322)	(3,112)
Other	22,262	9,824
Net cash provided by (used in) operating activities	69,592	69,623
Cash flows from investing activities		
Purchase of property, plant and equipment	(18,648)	(24,344)
Proceeds from sale of property, plant and equipment	3,374	126
Purchase of intangible assets	(25,631)	(13,005)
Purchase of investment securities	(1,219)	(1,057)
Proceeds from sale of investment securities	284	275
Purchase of shares of subsidiaries resulting in change in scope of consolidation	(48,196)	–
Payments for sale of investments in subsidiaries resulting in change in scope of consolidation	(5,603)	–
Proceeds from redemption of bonds of subsidiaries and associates	–	4,000
Transfers to escrow account	–	(7,700)
Other	(182)	62
Net cash provided by (used in) investing activities	(95,821)	(41,643)
Cash flows from financing activities		
Redemption of bonds with share acquisition rights	(9,621)	–
Repayments of lease liabilities	(2,984)	(2,734)
Purchase of treasury shares	(36,418)	(6)
Decrease (increase) in deposits for the purchase of treasury shares	(3,590)	–
Dividends paid	(30,895)	(30,882)
Other	(163)	21
Net cash provided by (used in) financing activities	(83,670)	(33,600)

	January 1, 2024 to September 30, 2024	January 1, 2025 to September 30, 2025
Effect of exchange rate changes on cash and cash equivalents	3,149	1,150
Net increase (decrease) in cash and cash equivalents	(106,750)	(4,470)
Cash and cash equivalents at beginning of period	403,083	244,681
Cash and cash equivalents at end of period	296,333	240,211

(5) Notes to Condensed Quarterly Consolidated Financial Statements

Notes on going concern assumption

No applicable items.

Segment information

The Group omitted information by reportable segment as the Group consists of only the one reportable segment, which is the Pharmaceuticals business.

Changes in presentation

Condensed Quarterly Consolidated Statement of Cash Flows

“Income taxes paid,” which had been presented separately under “Cash flows from operating activities” in the nine months ended September 30, 2024, has been changed to “Income taxes refund (paid)” to better reflect the actual situation. “Purchase of investment securities,” and “Proceeds from sale of investment securities,” which had previously been included in “Other” of “Cash flows from investing activities” in the nine months ended September 30, 2024, have been presented separately because its monetary materiality has increased. To reflect these changes in the presentation method, the Group has reclassified the amount in its Condensed Quarterly Consolidated Financial Statements for the nine months ended September 30, 2024.
As a result, negative ¥12,322 million presented as “Income taxes paid” in “Cash flows from operating activities” in the Condensed Quarterly Consolidated Statement of Cash Flows for the nine months ended September 30, 2024 was reclassified as “Income taxes refund (paid)” of negative ¥12,322 million, while negative ¥1,117 million presented as “Other” in “Cash flows from investing activities” was reclassified as “Purchase of investment securities” of negative ¥1,219 million, “Proceeds from sale of investment securities” of ¥284 million, and “Other” of negative ¥182 million.

Cash flow information

Negative ¥9,621 million in “Redemption of bonds with share acquisition rights” during the nine months ended September 30, 2024 is an expenditure related to bonds with share acquisition rights issued by Orchard Therapeutics before the business combination.
Negative ¥7,700 million in “Transfers to escrow account” during the nine months ended September 30, 2025 is a deposit made to the escrow account (account with restrictions on deposits and withdrawals) as part of the construction funds for a new biopharmaceutical drug substance manufacturing building.